Autologous CD34^+ and CD133^+ stem cells transplantation in patients with end stage liver disease

AIM:To assess the utility of an autologous CD34 + and CD133 + stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.METHODS:One hundred and forty patients with endstage liver diseases were randomized into two groups.Group 1,comprising 90 patients,received granulocyte colony stimulating factor for five days followed by autologous CD34 + and CD133 + stem cell infusion in the portal vein.Group 2,comprising 50 patients,received regular liver treatment only and served as a control group.RESULTS:Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients;13.6% of the patients showed stable states in the infused group.None of the patients in the control group showed improvement.No adverse effects were noted.CONCLUSION:Our data showed that a CD34 + and CD133 + stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.

Upregulated CD133 expression in tumorigenesis of colon cancer cells

AIM: To analyze the upregulated CD133 expression in tumorigenesis of primary colon cancer cells. METHODS: Upregulated CD133 expression in tumorigenesis of colorectal cancer cell lines (Lovo, Colo205, Caco-2, HCT116 and SW620) was analyzed by flow cytometry. Human colon cancer tissue samples were stained with anti-human CD133. SW620 cells were sorted according to the CD133 expression level measured by fluorescence-activated cell sorting. Spheroids of colorectal cancer cells were cultured with the hanging drop. Expression of CD133 and Lgr5 in spheroids of colorectal cancer cells and monolayer culture was detected by RT-qPCR. Spheroids of colorectal cancer cells were analyzed using anti-human CD133 with immunohistochemical staining. RESULTS: CD133 antigen was expressed in colorectal cancer cell lines (Lovo, Colo205, Caco-2, HCT116 and SW620) as well as in primary and metastatic human colon cancer tissues. However, the CD133 was differently expressed in these cell lines and tissues. The expression levels of CD133 and Lgr5 were significantly higher in spheroids of parental, CD133hi and CD133-cells than in their monolayer culture at the mRNA level (P < 0.05). Immunohistochemical staining of spheroids of CD133-cells showed that CD133 was highly expressed in colorectal cancer cell lines. CONCLUSION: Upregulated CD133 expression plays a role in tumorigenesis colorectal cancer cells, which may promote the expression of other critical genes that can drive tumorigenesis.

CD133:A cancer stem cells marker, is used in colorectal cancers

Colorectal cancer is one of the most common malignant tumors worldwide. A model of cancer development involving cancer stem cells has been put forward because it provides a possible explanation of tumor hierarchy. Cancer stem cells are characterized by their proliferation, tumorigenesis, differentiation, and selfrenewal capacities, and chemoradiotherapy resistance. Due to the role of cancer stem cells in tumor initiation and treatment failure, studies of cancer stem cell markers, such as CD133, have been of great interest. CD133, a five-transmembrane glycoprotein, is widely used as a marker to identify and isolate colorectal cancer stem cells. This marker has been investigated to better understand the characteristics and functions of cancer stem cells. Moreover, it can also be used to predict tumor progression, patient survival, chemoradiotherapy resistance and other clinical parameters. In this review, we discuss the use of CD133 in the identification of colorectal cancer stem cell, which is currently controversial. Although the function of CD133 is as yet unclear, we have discussed several possible functions and associated mechanisms that may partially explain the role of CD133 in colorectal cancers. In addition, we focus on the prognostic value of CD133 in colorectal cancers. Finally, we predict that CD133 may be used as a possible target for colorectal cancer treatment.

The Cross-talk between ROS and p38MAPKα in the Ex Vivo Expanded Human Umbilical Cord Blood CD133^+ Cells

This study investigated the correlation between and compared the effects of reactive oxygen species（ROS） and p38 mitogen-activated protein kinase α（p38MAPKα） in the ex vivo expanded umbilical cord blood（hUCB） CD133＋ cells.hUCB CD133＋ cells were cultured in the hematopoietic stem cells（HSCs） culture medium with N-acetylcysteine（NAC,an anti-oxidant）,p38MAPKα-specific inhibitor（SB203580） or their combination.The levels of ROS and expression of phosphorylated p38MAPKα（p-p38） in CD133＋ cells were flow cytometrically detected.The efficacy of ex vivo expansion was evaluated by the density of CD133＋ cell sub-group colony-forming cells（CFC） and cobblestone area-forming cells（CAFC） assay.Our results showed decreased ROS levels in NAC,SB203580,and their combination treatment groups were almost 37%,48%,and 85%,respectively.Furthermore,SB203580 abrogated the activation of p38MAPKα more obviously than NAC.Moreover,the CD133＋ cells in SB203580 treatment group had a 21.93±1.36-fold increase,and 14.50±1.19-fold increase in NAC treatment group,but only 10.13±0.57-fold increase in control group.In addition,SB203580 treatment led a higher level increase in the number of CFU and CAFC than NAC did.These findings suggested that,in expanded CD133＋ cells,ROS activates p38MAPKα,which,in turn,induces ROS production,and p38MAPKα might be the most suitable regulator in ROS-p38MAPKα pathway for the promotion of HSCs ex vivo expansion.

Cisplatin selects for CD133+cells in lung cancer cells

Objective Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer,but the chemoresistance of tumor cells continues to be a considerable challenge in the management of NSCLCs,leading to recurrence of most patients.CD133(prominin-1)is a five-transmembrane glycoprotein,and recent evidence suggests that CD133+cells are the cause of drug resistance and tumor recurrence.In this study,the correlation between cisplatin and CD133+cells was investigated systematically.Methods Four lung cancer cell lines,including A549,H460,801D and H1299,were treated with different concentrations of cisplatin.Cell viability was determined by MTT assay.Sphere-forming assay was performed to detect the capability of sphere-forming.CD133+cells was detected by BD FACScaliber flow cytometer.Results The results showed that cisplatin could increase the number of CD133+cells in both time-and dose-dependent manner.The enrichment would weaken but the proportion of CD133+cells was still higher than the basic level as incubation time extended after cisplatin was withdrawn.Compared with adherent culture,the proportion of CD133+cells was higher when the cells were maintained suspension culture.The proportion of CD133+cells significantly increased when cisplatin was provided in suspension culture.Conclusion These results revealed that cisplatin induces the enrichment of CD133+cells and CD133 is a new therapeutic target.Our data partially explained drug resistance to second-line chemotherapy in cisplatin-treated patients with NSCLCs.

CD133^+ gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity

AIM:To identify cancer stem cells(CSCs) in human gallbladder carcinomas(GBCs).METHODS:Primary GBC cells were cultured under serum-free conditions to produce floating spheres.The stem-cell properties of the sphere-forming cells,including self-renewal,differentiation potential,chemoresistance and tumorigenicity,were determined in vitro or in vivo.Cell surface expression of CD133 was investigated in primary tumors and in spheroid cells using flow cytometry.The sphere-colony-formation ability and tumorigenicity of CD133+ cells were assayed.RESULTS:In vitro culture experiments revealed thatfloating spheroids were generated from primary GBC cells,and these sphere-forming cells could generate new progeny spheroids in serum-free media.Spheroid cells were differentiated under serum-containing conditions with downregulation of the stem cell markers Oct-4,Nanog,and nestin(P < 0.05).The differentiated cells showed lower spheroid-colony-formation ability than the original spheroid cells(P < 0.05).Spheroid cells were more resistant to chemotherapeutic reagents than the congenetic adherent cells(P < 0.05).Flow cytometry showed enriched CD133+ population in sphereforming cells(P < 0.05).CD133+ cells possessed high colony-formation ability than the CD133-population(P < 0.01).CD133+ cells injected into nude mice revealed higher tumorigenicity than their antigen-negative counterparts(P < 0.05).CONCLUSION:CD133 may be a cell surface marker for CSCs in GBC.

Inhibitive effect of IL-24 gene on CD133^+ laryngeal cancer cells

Objective:To explore the inhihitive and apoptosis inductive effect of IL-24 genes on CD133^+laryngeal cancer cells in Hep-2 line.Methods:Human peripheral blood monocytes were isolated.The total RNA was extracted by using Trizol method and reverse transcripted into cDNA using RT-PCR method.Primers P1 and P2 was designed for the amplification of human IL-24 genes.After confirmation of agarose gel electrophoresis tests,TA was cloned into pMD19-T simple vector.Nhe Ⅰ and Xho Ⅰ double digesting human IL-24 and pIRES2-ZsGreen1 and eukaryotic expression vector were used to establish the pIRES2-ZsGreen1-hIL-24 vector,and detected by enzyme digestion and gene sequencing methods.Flow cytometry(FCM) was used to isolate CD133^+ cells from Hep-2 cells.CD133^+ cells were transfected with pIRES2-ZsGreen1-hIL-24 through liposome 2000.After detection,MTT and FCM were used to observe the effect of IL-24 gene on CD133^+ laryngeal cancer Hep-2 cells.Results:Lipotin mediated transfection of recombinant pIRES2-ZsGreen1-hIL-24 plasmid into CD133^+ Hep-2 could expressed IL-24 gene in cells stably.MTT results showed that IL-24 transfected group was significantly suppressed compared to empty vector group and control group(P<0.05);FCM results showed that the apoptosis rate of experimental group increased significantly compared to empty vector group and control group(P<0.05).Conclusions:IL-24 gene expressions can inhibit proliferation of CD133^+laryngeal cells in Hep-2 line and promote their apoptosis.

Influence of CD133^+ expression on patients' survival and resistance of CD133^+ cells to anti-tumor reagents in gastric cancer

Objective:To investigate the influence of CD133+expression on patients'survival and resistance of CD133+cells to anti-tumor agents in gastric cancer(GC).Methods:Influence of CD133 expression on prognosis was analyzed employing samples from patients with GC.GC cell lines were utilized to separate CD133+and CD133-subpopulations by immunomagnetic separation and to analyze the biological features of two subpopulations in vitro and in vivo,especially in resistant to anti-tumor reagents and its apoptotic mechanism.Results:The lower CD133+group showed a significantly better survival compared with the higher CD133+group.The highest content of CD133+subpopulations for KATO-III cells had stronger proliferative ability than CD133-subpopulations.A single CD133+cell was capable of generating new cell colony and the tumorigenicity rate in nude mice was100%for CD133+clonal spheres or for CD133+cells,but 0%for CD133-cells.Furthermore,the higher expression levels of Oct-4,Sox-2,Musashi-1 and ABCG2 in CD133+clonal spheres were identified compared with CD133+cells or CD133-cells.Under the treatment of anti-tumor reagents,CD133+cells had lower suppression rates compared with CD133-cells while lower level of Bcl-2 and higher level of Bax were found in CD133+cells compared with CD133-cells.Conclusions:The patients with lower CD133+expression had a better survival.Enriched CD133+cells in clonal sphere shared the ability to be self-renewable,proliferative,tumorigenic and resistant to anti-tumor agents as probably regulated by Bcl-2 and Bax.

5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells

Background and Objective:CD133-positive colon cancer stem like cells (CSLCs) are resistant to the conventional cytotoxic drug 5-fluorouracil (5-FU).Wnt signaling pathway plays important roles in colon cancer carcinogenesis and metastasis, and regulates the self-renewal capacity of CSLCs.In the present study, we explored the impact of 5-FU on Wnt signaling pathway of CD133-positive colon CSLCs, and the relation between Wnt signaling pathway and drug resistance of CD133-positive colon CSLCs.Methods:Magnetic activation cell separation was used to collect CD133-positive cells from colon cancer cell line DLD1, which was transfected with luciferase reporter for Wnt signaling activity.The activity of Wnt signaling pathway was compared between CD133-positive and CD133-negative cells.After the treatment with 1 μg/mL of 5-FU, the cell proliferation rates of DLD1 cells, CD133-positive cells, and CD133-negative cells were compared.After the treatment with 1 μg/mL and 10 μg/mL of 5-FU for 48 h, Wnt activity was compared between CD133-positive and CD133-negative cells.The expression of CD133 and cell apoptosis of CD133-positive cells was detected after exposure to 50 ng/mL of dickkopf (DKK)-1, a Wnt pathway inhibitor.Results:After the treatment with 5-FU, the cell proliferation rate of CD133-positive cells was higher than that of CD133-negative cells and the sensitivity of CD133-positive cells to 5-FU decreased.Wnt activity was higher in CD133-positive cells than in CD133-negative cells [(46.3±0.3)% vs.(33.9±2.7)%, P=0.009].After the treatment with 1 μg/mL and 10 μg/mL of 5-FU, Wnt activity of CD133-positive cells was (90.1±10.0)% (P=0.012) and (52.9±2.5)% (P=0.047), respectively, whereas that of CD133-negative cells was (35.5±3.3)% (P=0.434) and (26.5±0.4)% (P=0.046), respectively.CD133 expression in CD133-positive cells decreased from (87.2±5.3)% to (60.6±3.1)% (P=0.022) after treatment with DKK-1, whereas the cell apoptosis rate increased from (11.8±0.2)% to (28.3±0.6)% (P=0.013).Conclusions:Wnt activity is higher in CD133-positive DLD1 cells than in CD133-negative DLD1 cells.5-FU can upregulate Wnt activity of CD133-positive colon CSLCs.Blocking Wnt activity may reverse drug sensitivity of CD133-positive cells to 5-FU.

Proliferation Characteristics of CD133+ Cell Population in Colorectal Cancer

In this study,CD133+ subpopulations were isolated from 41 primary colorectal cancer tissues,the proliferation and cell cycle distribution of the cells were examined without in vitro expansion,and then compared to those of cell lines.The detection of CD133 in colorectal cancer tissues,isolation of CD133+ and CD133-epithelial subpopulations,Ki-67/DNA multiparameter assay and cell volume analysis were flow cytometrically conducted.The results showed that Ki-67 expression was correlated with CD133 level in primary cancer tissues,while cell cycle G 2 /M phase distribution or clinicopathological characteristics was not.In addition,the CD133+ cells showed larger cell volume and higher Ki-67 expression as compared with CD133-cells.But there was no statistically significant difference in G 2 /M phase distribution between the two subpopulations.Our results demonstrated that the CD133+ subpopulation in colorectal cancer tissue contained more actively cycling and proliferating cells,which was not correlated to clinicopathological factors but might contribute to tumor progression and poor clinical outcome.

双特异性CAR-T细胞对EGFRvⅢ^(+)/CD133^(+)胶质瘤干细胞的靶向杀伤

目的:制备双特异性CAR-T(bs CAR-T)细胞,观察其对表达表皮生长因子Ⅲ型突变阳性(EGFRvⅢ^(+),简称vⅢ^(+))和CD133^(+)胶质瘤干细胞的靶向杀伤作用。方法:基于前期研制的vⅢ/CD133双特异性微抗体和二代CAR构建的双特异性CAR(bs CAR),制备慢病毒载体转染人外周血T细胞,FCM和WB法检测bs CAR转染效率和表达水平。bs CAR-T细胞和vⅢ^(+)/CD133^(+)U87胶质瘤干细胞共培养,乳酸脱氢酶(LDH)释放实验、IFN-γ分泌实验检测其特异性杀伤作用和对IFN-γ分泌的促进作用。制备裸鼠vⅢ^(+)/CD133^(+)U87干细胞移植瘤模型检测bs CAR-T细胞对移植瘤生长的抑制作用。结果:vⅢsc Fv和CD133sc Fv通过重叠PCR无缝连接入二代CAR表达框(S-vⅢscFv/CD133scFv-Hinge-TM-CD137-CD3ζ)中,然后克隆入p CDH-MSCV-MCS-EF1-copGFP载体的Eco RⅠ和Bam HⅠ位点(pbs CAR)。3种质粒(p VSV-G、p CMV-d R8.9和pbs CAR)共转染HEK293T细胞制备慢病毒载体,转染外周血T细胞,FCM检测bs CAR表达率为71.1%,WB法结果显示bs CAR表达正确。bs CAR-T细胞和vⅢ^(+)/CD133^(+)U87干细胞共培养检测结果显示,bs CAR-T细胞对胶质瘤干细胞具有特异性杀伤作用,与效靶比呈正比;IFN-γ分泌量为(2350.6±92)pg·m L^(-1),明显高于对照组(P<0.01)。裸鼠移植瘤动物模型显示,bs CAR-T细胞在体内具有明显的移植瘤抑制作用(P<0.01)。结论:bs CAR-T细胞能够特异性靶向杀伤vⅢ^(+)/CD133^(+)胶质瘤干细胞,实验结果为促进实体瘤的细胞免疫治疗提供了实验依据。

The CD133/1⁺cell subset from human subcutaneous adult fat retains hemogenic potential

Research has shown that cells from adult fat tissue can effect long-term blood reconstitution. Fat-derived multipotentiality was ascribed to CD34+ perivascular populations from its prominent microvasculature, that represent mostly non-hemogenic, mesenchymal cells, although this tissue contains a CD34+45+ subset committed to a hemogenic fate. Here, in order to analyze cell subsets presenting hemogenic capabilities within fat, CD133/1+ and pericytes, the latter defined by CD140b (PDGFRb, Platelet-Derived Growth Factor Receptor Beta) expression, were immunomagnetically selected from stromal-vascular fractions (SVF). In Vitro Colony Forming Unit (CFU) assays were negative for CD140b+ pericytes and positive for CD133/1+ cells when a prolonged CFU assay was performed, revealing fat as another store of primitive progenitors that retain hemogenic potential.

Percoll Gradient Optimization for Blood CD133+ Stem Cell Recovery

Circulating CD133+ stem cells from the peripheral blood have been shown to be able to differentiate into numerous cell lineages. However, adults have only a small number of these circulating stem cells. The aim of the present study was to assess a new isolation and enrichment technique for CD133+ stem cells from peripheral blood with the use of Percoll density gradients. Our results demonstrated the presence of two large mononuclear bands when whole blood was centrifuged with 48% and 50% Percoll concentrations. Flow cytometric analysis (FACS) revealed a major CD133+ enrichment at the 48% Percoll concentration in one of the two bands. Further culture of these cells resulted in the formation of multiple colony-forming units. Our results suggest an advantage from using a simple Percoll gradient for successful CD133+ cell recovery, which could aid in differentiation and transplantation protocols.

CD133^(+)结肠癌细胞区域变异位点在结肠癌免疫逃逸中的作用研究

目的分析探讨CD133^(+)结肠癌细胞3-UTR区域rs2240688变异位点在结肠癌免疫逃逸中的作用。方法检测CD133^(+)结肠癌细胞3-UTR区域rs2240688位点单核苷酸多态性,并分别检测不同基因型CD133^(+)结肠癌细胞侵袭迁移能力以及NK-92细胞对不同基因型CD133^(+)结肠癌细胞的细胞毒力。结果基因型为G/G的CD133^(+)结肠癌细胞侵袭迁移能力最强,而基因型为T/T的CD133^(+)结肠癌细胞侵袭迁移能力最弱(P均<0.05);NK-92细胞对基因型为G/G的CD133^(+)结肠癌细胞的细胞毒力最弱,而对基因型为T/T的CD133^(+)结肠癌细胞的细胞毒力最强(P均<0.05)。结论CD133^(+)结肠癌细胞3-UTR区域单核苷酸多态性位点基因多态性能够参与机体的免疫逃逸,对CD133^(+)肿瘤干细胞进行深入研究,有望成为结直肠癌临床治疗的新靶点。

CD10、CA9、CD133表达与索拉非尼或舒尼替尼一线治疗转移性肾透明细胞癌患者预后的相关性

目的分析CD10、CA9、CD133表达与索拉非尼或舒尼替尼一线治疗转移性肾透明细胞癌(mccRCC)患者预后的相关性。方法回顾性纳入80例接受索拉非尼或舒尼替尼一线治疗的mccRCC患者,对肿瘤组织标本中CD10、CA9、CD133进行免疫组织化学(IHC)染色,分析各标志物表达与临床病理变量的相关性,采用单因素和多因素Cox比例风险模型分析PFS和OS的预后因素,并对CA9表达与治疗亚组患者的PFS和OS进行Kaplan-Meier生存分析。结果37例(46.25%)患者出现无进展生存期(PFS)的随访结局,中位PFS(mPFS)为24.9个月(95%CI:16.5~33.2)。55例(68.75%)患者死亡,中位总生存期(mOS)为44.2个月(95%CI:14.6~73.7)。CD10低表达与Fuhrman高分级相关(χ^(2)=6.241,P=0.012),CA9低表达与淋巴结转移(χ^(2)=5.952,P=0.015)和转移器官个数≥2个(χ2=8.205,P=0.004)相关。单因素分析显示Fuhrman分级、转移器官数以及淋巴结转移是PFS的预后因素(P<0.05),转移器官数、淋巴结转移及CA9表达是OS的预后因素(P<0.05);多因素分析显示Fuhrman分级是PFS的独立预后因素(HR=2.457,95%CI:1.126~5.365,P=0.024),转移器官数是OS的独立预后因素(HR=1.857,95%CI:1.048~3.290,P=0.034)。治疗亚组患者生存分析,索拉非尼组中CA9高表达与患者更长的OS相关(HR=0.401,95%CI:0.204~0.787,P=0.008)。结论CA9低表达是OS的非独立危险因素,而CD10、CD133不能作为mccRCC的预后因素。CA9低表达的mccRCC患者从索拉非尼和舒尼替尼治疗中生存获益较少,可根据指南选择靶向免疫联合或双免联合治疗以改善预后。

人脐血CD133^+细胞体外短期培养中生物学特性的变化

为了解脐血CD133+细胞的生物学特性及其在体外短期扩增培养中的变化 ,探讨其体外扩增的可行性 ,初步观察了脐血CD133+细胞的免疫表型、细胞周期、端粒酶活性以及粘附分子的表达等生物学特性及其在体外扩增中的动态变化并与CD34+细胞进行比较。结果显示 ,新鲜脐血CD133+和CD34+细胞的含量分别为 ( 1.0 5±0 73) %和 ( 1.4 0± 0 .5 6 ) % ,CD34+细胞中 79.6 2 %为CD133+CD34+细胞 ,而CD133+细胞中 97%以上为CD133+CD34+细胞。短期扩增培养结果显示 ,CD133+细胞组扩增第 10天 ,CD133+,CD133+CD34+和CD34+CD38-细胞以及第 6天的CFU mix ,HPP CFC和CD34+CD38-细胞的扩增倍数要高于CD34+细胞组 ( P <0 .0 5 ) ;扩增中 ,CD133+CD34+细胞的比例逐渐下降 ,而CD133-CD34+和CD133-CD34-细胞的比例则逐渐上升。新鲜脐血CD133+和CD34+细胞的端粒酶活性较低 ,但高于CD34-细胞。扩增 1周后 ,端粒酶活性明显上调 ,15天以后又逐渐下降 ;90 %以上脐血CD133+细胞表达CD11a ,CD4 9d和CD5 4 ,约 5 0 %表达CD6 2L。扩增早期 ,CD4 9d表达上调 ,CD11a表达无明显变化 ,而CD5 4和CD6 2L则有下调趋势 ,随着扩增时间的延长 ,各种粘附分子的表达均有不同程度的下调。在整个扩增过程中 ,大部分CD34+细胞仍然表达CD11a,CD4 9d和CD5 4?

肿瘤干细胞标志物CD133、CD44、SOX2、OCT4、ALDH1在非小细胞肺癌组织中的表达及临床意义

目的研究肿瘤干细胞标记物CD133、CD44、SOX2、OCT4、ALDH1在非小细胞肺癌(NSCLC)组织中的表达及临床意义,为探索非小细胞肺癌肿瘤干细胞提供参考。方法采用免疫组织化学方法检测70例NSCLC组织、14例非癌组织中的CD133、CD44、SOX2、OCT4、ALDH1蛋白的表达并对结果进行分析。结果 (1)CD133、CD44、SOX2、OCT4、ALDH1在70例NSCLC组织中的阳性表达率分别为88.57%、98.57%、100%、100%、100%,强阳性表达率分别为48.57%、67.14%、67.14%、31.43%、50%;CD133、C C D 4 4在N S C L C与非癌组织中的表达差异存在统计学意义(P均<0.0001),SOX2、OCT4、ALDH1在NSCLC与非癌组织中的表达差异无统计学意义(P均>0.05)。(2)随着病理级别的升高,CD133、CD44、SOX2、OCT4及ALDH1的表达呈上升趋势,分化越低的NSCLC表达上述指标的概率越高,其中CD133、SOX2、OCT4的表达在高、中、低分化组织中差异存在统计学意义(P值分别为0.001、0.040、<0.0001);CD133的表达在吸烟史、分化程度、淋巴结转移、肿瘤分期四个因素上差异存在统计学意义(P值分别为0.033、0.001、0.033、0.046);CD44与SOX2的表达在年龄上的差异存在统计学意义(P值分别为0.001、0.040)。结论 NSCLC组织中CD133、CD44、SOX2、OCT4、ALDH1阳性率高,CD133、CD44的表达明显高于非癌组织;CD133、SOX2、OCT4与NSCLC的恶性程度有关;CD44与SOX2与年龄因素有关。

肿瘤干细胞标志物CD133在非小细胞肺癌中的表达及临床意义

【目的】研究肿瘤干细胞标志物CD133在非小细胞肺癌(NSCLC)组织中表达的临床意义。【方法】用免疫组织化学方法检测77例手术切除的NSCLC组织中CD133的表达,分析CD133表达与患者吸烟指数、组织学类型、组织分化程度、淋巴结转移、肿瘤T分期、N分期和患者预后之间的关系。【结果】77例NSCLC患者到随访结束时死亡率72.73%(56/77),术后生存时间1～84(s=19)月、3年生存率为32.47%(25/77);无淋巴结结转移组NSCLC的中位生存时间和3年生存率高于有淋巴结转移组(P<0.05)。CD133阳性表达率51.9%(40/77);CD133的表达与淋巴结转移呈正相关(r=0.246,P<0.05),与患者手术后生存期呈负相关(P<0.05)。COX多因素分析仅癌肿病理类型和CD133蛋白表达为影响生存率的独立因素。【结论】NSCLC的淋巴结转移和病理类型与预后有密切关系;肿瘤干细胞标志物CD133蛋白的表达与NSCLC的淋巴结转移和预后密切相关。

5氟尿嘧啶上调干细胞标记物CD133在结肠癌细胞中的表达

目的:研究通过5氟尿嘧啶(5-FU)对结肠癌干细胞标记物CD133表达的影响,探讨5-FU对结肠癌干细胞的影响。方法:用流式细胞仪检测CD133在结肠癌细胞株表面的表达,磁珠细胞分离的方法分离结肠癌细胞株DLD1中CD133阳性和阴性的细胞群,细胞克隆形成实验检测2群细胞的自我更新能力,新型四唑氮盐方法(MTS)检测2群细胞对5-FU敏感性的差异,qPCR方法检测5-FU处理结肠癌细胞后CD133 mRNA水平的变化。结果:结肠癌细胞株DLD1、HT29、SW480、HCT116、Lovo、RKO细胞表面CD133的表达率分别为30.20%、82.00%、0.34%、91.80%、85.30%、0.28%。DLD1细胞中以CD133为标记有2群明显的细胞,MACS方法分离后阳性细胞群中CD133为87.21%±5.33%,而阴性细胞群中阴性细胞的比例为84.30%±4.65%;CD133阳性的细胞与未分离及CD133阴性细胞相比,克隆形成能力强(46.33%±4.44%vs31.00%±2.00%,P<0.05),对5-FU的敏感性下降20%,P<0.01。在DLD1和HT29细胞中,5-FU1mg/L上调CD133 mRNA水平的表达,从1升为1.684±0.012(P<0.01)、HT29细胞从30.702±0.284升为49.379±0.460(P<0.01)。结论:与CD133阴性细胞相比CD133阳性细胞克隆形成能力强,对5-FU的敏感性下降;5-FU上调干细胞标记物CD133 mRNA水平的表达,CD133阳性的结肠癌干细胞在5-FU的治疗过程中被富集。